GLP-1 Medications: What They Are, Who They’re For, and Why Nutrition Support Still Matters
GLP-1 receptor agonists have quickly become one of the most talked-about topics in nutrition and health care. Many people are asking the same question: should I take one?
As a registered dietitian, my answer is nuanced. These medications can be powerful, evidence-based tools for the right person, but they are not a quick fix and they are not appropriate for everyone. Most importantly, medication alone does not replace the need for nutrition care, muscle preservation, and healing your relationship with food.
Let’s look at what the science shows and what often gets missed in the conversation.
GLP-1 receptor agonists are prescription medications that mimic a natural hormone in the body called glucagon-like peptide-1, or GLP-1. This hormone is released after eating and helps regulate blood sugar control, appetite and fullness, stomach emptying, and insulin and glucagon secretion.
By enhancing this natural signal, GLP-1 medications can improve blood sugar in type 2 diabetes, reduce hunger and food intake, and support meaningful weight loss in some individuals. Large clinical trials also show improvements in cardiometabolic health and reductions in cardiovascular risk in certain high-risk populations, meaning these medications are about health outcomes, not just weight.
Despite how widely they are discussed online, GLP-1 medications were developed for medical treatment of chronic disease, not cosmetic weight loss. They are generally prescribed for type 2 diabetes, particularly when blood sugar remains above target or when cardiovascular or kidney risk is present, and for chronic obesity affecting health.
Chronic obesity is typically defined as a body mass index of 30 or higher, or 27 or higher with a weight-related medical condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease. This distinction matters because when someone does not meet medical criteria, the balance of risk, benefit, and long-term need changes significantly.
We now have multi-year randomized clinical trial data on GLP-1 medications showing sustained weight loss while on treatment for up to two years or more, reduced major cardiovascular events in people with overweight or obesity and existing heart disease, kidney-protective effects in people with type 2 diabetes and chronic kidney disease, and weight regain after stopping medication that often trends back toward baseline biology.
This last point is especially important. GLP-1 medications often function like chronic therapy, similar to blood pressure or cholesterol medication, rather than a short-term course. This is not failure. It is physiology.
Most side effects are gastrointestinal, including nausea, reflux, constipation or diarrhea, and early fullness. These are usually most noticeable during dose increases and often improve with time and appropriate nutrition strategies.
Less common but important risks include gallbladder complications, symptoms of pancreatitis, worsening diabetic retinopathy in certain high-risk diabetes cases, and contraindications in pregnancy or specific thyroid cancer histories. This is why medical screening and monitoring are essential.
One of the biggest misconceptions is that if someone takes the medication, nutrition no longer matters. In reality, nutrition becomes more important, not less.
Because appetite decreases, there is a higher risk of inadequate protein intake, loss of lean muscle mass, low overall energy intake, micronutrient deficiencies, and fatigue or weakness. Weight loss without muscle preservation is not true health improvement. Muscle mass is essential for metabolism, strength, blood sugar control, long-term weight stability, and healthy aging.
This is where dietitian support becomes critical. Working with a dietitian helps ensure adequate protein intake, resistance training guidance, and balanced fueling to protect lean mass, along with strategies to manage side effects such as smaller, more frequent meals, gradual fiber intake, hydration planning, and adjusting fat intake if nausea occurs. Dietitian care also helps ensure sufficient calories, micronutrients, and hydration even when appetite is low.
GLP-1 medications can reduce hunger, but they do not automatically resolve emotional eating, binge–restrict cycles, food guilt or fear, body image distress, or diet culture pressure. In some cases, appetite suppression can even mask disordered eating patterns rather than address them.
True long-term well-being often requires nutrition counseling, behavioral and emotional support, body image work, and compassionate, non-restrictive approaches to food. Medication may be one tool, but it is rarely the only tool.
For people who medically qualify, GLP-1 medications can be effective, evidence-based, health-improving, and even life-changing, and I fully support their thoughtful use. But when someone does not meet medical criteria, is driven mainly by body dissatisfaction, wants a quick or temporary fix, or has an unhealed relationship with food, medication alone is unlikely to provide the outcome they are truly seeking. In these situations, other approaches may be safer, more sustainable, and more healing.
GLP-1 medications are important medical advances in the treatment of type 2 diabetes, chronic obesity, and cardiovascular and kidney risk. They are not trends or cosmetic tools. They work best when combined with medical supervision, dietitian-guided nutrition care, muscle-preserving lifestyle support, and attention to emotional health around food.
Because real health is never just about weight loss. It is about strength, nourishment, stability, and long-term well-being.
If you are considering a GLP-1 medication, the most important step is not choosing the drug. It is building the right care team to support your whole health, and that should always include a dietitian.
References:
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … STEP 1 Study Group. (2021).
Once-weekly semaglutide in adults with overweight or obesity.
New England Journal of Medicine, 384(11), 989–1002.
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., … STEP 5 Study Group. (2022).
Effect of continued weekly semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity.
Nature Medicine, 28, 2083–2091.
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., … SURMOUNT-1 Investigators. (2022).
Tirzepatide once weekly for the treatment of obesity.
New England Journal of Medicine, 387(3), 205–216.
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., … STEP 1 Extension Study Group. (2022).
Weight regain and cardiometabolic effects after withdrawal of semaglutide.
Diabetes, Obesity and Metabolism, 24(8), 1553–1564.
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Husain, M., … SELECT Investigators. (2023).
Semaglutide and cardiovascular outcomes in obesity without diabetes.
New England Journal of Medicine, 389, 2221–2232.
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., … LEADER Trial Investigators. (2016).
Liraglutide and cardiovascular outcomes in type 2 diabetes.
New England Journal of Medicine, 375, 311–322.
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … SUSTAIN-6 Investigators. (2016).
Semaglutide and cardiovascular outcomes in type 2 diabetes.
New England Journal of Medicine, 375, 1834–1844.
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., … REWIND Investigators. (2019).
Dulaglutide and cardiovascular outcomes in type 2 diabetes.
The Lancet, 394(10193), 121–130.
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., … FLOW Trial Committees and Investigators. (2024).
Semaglutide and renal outcomes in patients with type 2 diabetes and chronic kidney disease.
New England Journal of Medicine.
Drucker, D. J. (2018).
Mechanisms of action and therapeutic application of glucagon-like peptide-1.
Cell Metabolism, 27(4), 740–756.
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., … McMurray, J. J. V. (2019).
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.
The Lancet Diabetes & Endocrinology, 7(10), 776–785.